Susi Geiger – författare

What is the role of activists and civil society in defining and defending the collective good in healthcare, especially in cases where that good seems to be heavily shaped by market dynamics? Presenting conceptual and empirical studies from a variety of healthcare contexts and theoretical perspectives, this book addresses this vital question by drawing together multidisciplinary scholarship from Science and Technology Studies, Sociology, Organisation Studies, Marketing, Philosophy, and Public Health. Healthcare has undergone three major changes over the past decades: the advent of personalized medicine, the marketization of public care systems, and the digitalization of healthcare services. This book maps these changes and illustrates the extent to which they are interlinked to produce a seemingly unstoppable move toward individualization in healthcare. The book also highlights the tensions and challenges arising from these interlinkages, and traces how activists react to these tensions to argue for and defend the common good. It thus sketches a multifaceted picture of healthcare activism in the 21st century as civil society responds to these dynamics at the crossroads of markets and morals, economic and social justifications, individual and collective, and digital and non-digital worlds. Crucially, it also highlights potential solutions for heightening patient voices and broadening participation in healthcare markets in a post Covid-19 world.

What is the role of activists and civil society in defining and defending the collective good in healthcare, especially in cases where that good seems to be heavily shaped by market dynamics? Presenting conceptual and empirical studies from a variety of healthcare contexts and theoretical perspectives, this book addresses this vital question by drawing together multidisciplinary scholarship from Science and Technology Studies, Sociology, Organisation Studies, Marketing, Philosophy, and Public Health. Healthcare has undergone three major changes over the past decades: the advent of personalized medicine, the marketization of public care systems, and the digitalization of healthcare services. This book maps these changes and illustrates the extent to which they are interlinked to produce a seemingly unstoppable move toward individualization in healthcare. The book also highlights the tensions and challenges arising from these interlinkages, and traces how activists react to these tensions to argue for and defend the common good. It thus sketches a multifaceted picture of healthcare activism in the 21st century as civil society responds to these dynamics at the crossroads of markets and morals, economic and social justifications, individual and collective, and digital and non-digital worlds. Crucially, it also highlights potential solutions for heightening patient voices and broadening participation in healthcare markets in a post Covid-19 world.

What is the role of activists and civil society in defining and defending the collective good in healthcare, especially in cases where that good seems to be heavily shaped by market dynamics? Presenting conceptual and empirical studies from a variety of healthcare contexts and theoretical perspectives, this book addresses this vital question by drawing together multidisciplinary scholarship from Science and Technology Studies, Sociology, Organisation Studies, Marketing, Philosophy, and Public Health. Healthcare has undergone three major changes over the past decades: the advent of personalized medicine, the marketization of public care systems, and the digitalization of healthcare services. This book maps these changes and illustrates the extent to which they are interlinked to produce a seemingly unstoppable move toward individualization in healthcare. The book also highlights the tensions and challenges arising from these interlinkages, and traces how activists react to these tensions to argue for and defend the common good. It thus sketches a multifaceted picture of healthcare activism in the 21st century as civil society responds to these dynamics at the crossroads of markets and morals, economic and social justifications, individual and collective, and digital and non-digital worlds. Crucially, it also highlights potential solutions for heightening patient voices and broadening participation in healthcare markets in a post Covid-19 world.

This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.

This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.

This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system. Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health. This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.

This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system. Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health. This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.

Sales Management offers a global perspective on the opportunities and issues facing today's sales managers. Current textbooks have failed to move beyond the US context; Sales Management provides unique access to European and international experts, with globally relevant case studies.Accompanying online resources for this title can be found at bloomsburyonlineresources.com/sales-management. These resources are designed to support teaching and learning when using this textbook and are available at no extra cost.

Market studies is a newly emerging field dedicated to understanding the origins, core concepts, theories and methods currently being used and developed to examine markets in the making. Providing a unique overview that introduces, positions and develops this highly fertile area of research, Market Studies is the first book to consolidate its themes, tools and methods in a single, comprehensive volume. Topics covered include: market organization and design; performativity in and around markets; valuation; market places and spaces; methods that may be utilized in studying markets; the field's relation to adjacent disciplines; the future of markets. Deploying a sensitivity for the socio-material constitution of markets, the authors put market practices at the centre of inquiry and offer insights into the future and potential impact of market studies research. The contemporary, practical and interdisciplinary approach is strengthened by multiple examples of original empirical research into markets.

Market studies is a newly emerging field dedicated to understanding the origins, core concepts, theories and methods currently being used and developed to examine markets in the making. Providing a unique overview that introduces, positions and develops this highly fertile area of research, Market Studies is the first book to consolidate its themes, tools and methods in a single, comprehensive volume. Topics covered include: market organization and design; performativity in and around markets; valuation; market places and spaces; methods that may be utilized in studying markets; the field's relation to adjacent disciplines; the future of markets. Deploying a sensitivity for the socio-material constitution of markets, the authors put market practices at the centre of inquiry and offer insights into the future and potential impact of market studies research. The contemporary, practical and interdisciplinary approach is strengthened by multiple examples of original empirical research into markets.

This comprehensive Handbook examines innovation in the pharmaceutical sector using ideas drawn from the interdisciplinary field of science and technology studies (STS). Leading experts present diverse social science approaches to pharmaceuticals, consolidating existing research and providing an agenda for future research in this area.International contributors critically analyse the global dynamics of knowledge production, the political economy of manufacturing, the making of markets, their regulation and governance, and the diverse ecologies of consumption for pharmaceuticals. The Handbook deconstructs the constituent parts that make up the social, political and economic power of the pharmaceutical sector while also foregrounding alternatives to the dominant mode of innovation and production.The Handbook of Pharmaceutical Science and Technology Studies is an essential resource for students and scholars in STS, economics, innovation and technology, health and social policy. It is also a valuable read for policymakers, professionals and practitioners involved in global bio-pharma innovation.

Sales Management offers a global perspective on the opportunities and issues facing today''s sales managers. Current textbooks have failed to move beyond the US context; Sales Management provides unique access to European and international experts, with globally relevant case studies.

Concerned Markets tackles the intersection between markets and politics, investigating the very current issue of designing markets to include multiple values.When political, social, technological and economic interests, values, and perspectives interact, market order and performance become contentious issues of debate. Such 'hot' situations are becoming increasingly common and make for rich sites of research. With expert empirical contributions investigating the organization of such 'concerned' markets, this book is positioned at the centre of the rapidly growing area of interdisciplinary market studies. Markets investigated include those for palm oil, primary health care and functional foods. The authors also examine markets and environmental concerns as well as better market design for those at the bottom of the pyramid.Scholars, postgraduate and PhD level students in finance, economic sociology, marketing, organization theory and economics will find this book essential reading. Policymakers and practitioners will benefit from the fresh insight into the design and maintenance of market systems.Contributors include: L. Araujo, F. Azimont, R. Chakrabarti, F. Cochoy, S. D'Antone, G. Dix, S. Geiger, D. Harrison, J. Hauber, L. Johansson, H. Kjellberg, A. Mallard, K. Mason, W.I. Onyas, C. Ruppert-Winkel, A. Ryan, R. Spencer, I. Stigzelius